Mirvetuximab soravtansine: an oasis in the desert?

Int J Gynecol Cancer. 2024 Apr 1;34(4):478-479. doi: 10.1136/ijgc-2024-005400.
No abstract available

Keywords: ovarian cancer.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Female
  • Humans
  • Immunoconjugates*
  • Maytansine* / adverse effects
  • Maytansine* / analogs & derivatives
  • Ovarian Neoplasms*

Substances

  • mirvetuximab soravtansine
  • Antibodies, Monoclonal, Humanized
  • Maytansine
  • Immunoconjugates